GRFS

Based on Grifols, S.A.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.

What does Grifols do?

Grifols collects human plasma and transforms it into life-saving medicines for patients with immune deficiencies, hemophilia, and rare diseases. The company also produces diagnostic tools, clinical nutrition products, and biological materials for research — serving hospitals, health systems, and distributors globally.

Does GRFS pay dividends?

Yes, Grifols pays a regular dividend. This makes it relevant for investors seeking income from the healthcare sector. The dividend is funded alongside the company's ongoing capital investment in plasma collection infrastructure and product development.

When does GRFS report earnings?

Grifols reports on a quarterly cadence, as is standard for internationally listed healthcare companies. For the exact schedule and most recent results, check the investor relations section of Grifols' official website.

Is GRFS a good stock to buy?

UQS Score rates GRFS as Good overall. The Valuation pillar is Attractive, which may interest value-oriented investors. However, the Weak Risk pillar is a meaningful consideration. The complete pillar breakdown is available to UQS Pro members for a deeper view.

Is GRFS overvalued?

Based on UQS Score analysis, GRFS carries an Attractive Valuation rating, suggesting it may be trading at a discount relative to its fundamental profile. This does not constitute a buy recommendation — investors should weigh this against the Weak Risk rating before drawing conclusions.

How does GRFS compare to its competitors?

Grifols is differentiated by its deep specialization in plasma-derived therapies, which sets it apart from broader pharmaceutical peers like Biogen and Daiichi Sankyo. Compared to Organon, Grifols targets a different patient population. Each competitor carries its own UQS Score profile, viewable on their respective pages.

What is GRFS's market cap bracket?

Grifols is classified as a mid-cap company. This places it in a tier that typically offers more growth potential than mega-cap peers but may carry more volatility and less liquidity than the largest healthcare names.

Who founded Grifols?

The Grifols family has been central to the company's history since its origins in Spain. The publicly listed entity in its current form was established in 2011. For detailed founding history, Grifols' corporate website provides a comprehensive timeline.

Is GRFS a long-term quality investment?

UQS Score's long-term quality indicator for GRFS is Good, driven by an Attractive Valuation and diversified divisional structure. The Weak Risk pillar is the primary factor that tempers the long-term quality case. Pro members can access the full pillar breakdown to assess fit for their own time horizon.

What is the main competitive advantage of Grifols?

Grifols' core advantage lies in its integrated plasma collection and manufacturing infrastructure, which is difficult and capital-intensive to replicate. Its focus on rare and chronic disease therapies — where patient need is consistent — provides a degree of demand stability not found in more discretionary healthcare segments.

What sector does GRFS belong to?

Grifols operates in the Healthcare sector, specifically within the plasma-derived biologics and diagnostics space. It serves both public health systems and private healthcare providers, giving it exposure to both government-funded and commercial healthcare spending.

Is GRFS a growth stock or value stock?

Based on UQS pillar ratings, GRFS leans toward the value side of the spectrum. Its Valuation pillar is rated Attractive while Growth is Neutral, suggesting the investment case rests more on current pricing than on near-term expansion momentum.

Grifols, S.A. has average quality metrics, with room for improvement in margins or capital efficiency.

Grifols, S.A. shows steady but unspectacular growth, typical for mature companies.

Grifols, S.A. presents elevated risk with concerns around leverage or financial stability.

Grifols, S.A. appears attractively valued relative to its earnings, cash flows, and sector peers.

Grifols, S.A. possesses some competitive advantages but faces meaningful competition. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for GRFS.

The UQS (Unified Quality Score) for Grifols, S.A. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.

Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.

Moat (25%) assesses Grifols, S.A.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.

Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.

Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.

Valuation (15%) measures whether Grifols, S.A. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.

Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.